Oramed CEO to be Panelist at BIO International Convention Breakout Session on Israel Becoming Biotech Leader

Oramed CEO to be Panelist at BIO International Convention Breakout Session on
                        Israel Becoming Biotech Leader

PR Newswire

JERUSALEM, April 22, 2013

JERUSALEM, April 22, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a
developer of oral delivery systems, announced today that the Company's CEO
Nadav Kidron has been invited to be a panelist for a breakouts session at the
BIO International Convention in Chicago, Illinois, USA. The breakout session,
titled "Can Israel Become the Next Biotech Start-Up Nation?" will take place
on Tuesday, April 23^rd, from 9:00-9:45am during the International Market
Briefings Track.

Panel Description:

In the last 20 years, Israel has become a model for high tech
entrepreneurship. A country of 8 million people, Israel is home to a vibrant
academic biomedical research sector, a global pharmaceutical company and
several public biotech companies. Yet, the success of Israel's biotech sector
pales in comparison to its high-tech industry. What can be learned from the
Israeli Hi-tech Innovation and Entrepreneurship model and how can it be
applied to biotech? What can Israel learn from other success models in
biotechnology such as Massachusetts or California? Which regional partnerships
can best leverage Israel's potential? What is the optimal positioning for
Israeli Biotech to encourage biopharma companies and investors to step up
their involvement?

For more information on the panel please visit:
http://mybio.zerista.com/event/member/64237

The BIO International Convention is hosted by the Biological Industry
Organization (BIO) and is one of the largest and most widely attended annual
conferences in the biotechnology sphere. For more information on BIO Chicago
please visit: http://convention.bio.org/

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs and vaccines currently delivered via injection.
Established in 2006, Oramed's technology is based on over 30 years of research
by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is
seeking to revolutionize the treatment of diabetes through its proprietary
flagship product, an orally ingestible insulin capsule (ORMD-0801) currently
approaching Phase 2 clinical trials under U.S. IND, and with its oral
exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a
trials. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release,
please visithttp://www.oramed.com.

The company's fact sheet,the content of which is not part of this press
release, can be viewedhere.

Forward-looking statements: This press release contains forward-looking
statements. For example, we are using forward-looking statements when we
discuss our oral insulin and oral exenatide candidates approaching Phase 2
clinical trials under U.S. IND and 2a clinical trials, respectively. These
forward-looking statements are based on the current expectations of the
management of Oramed only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in obtaining
regulatory approval or patent protection for our product candidates;
competition from other pharmaceutical or biotechnology companies; and our
ability to obtain additional funding required to conduct our research,
development and commercialization activities. In addition, the following
factors, among others, could cause actual results to differ materially from
those described in the forward-looking statements: changes in technology and
market requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce new
technologies, products and applications; lack of validation of our technology
as we progress further and lack of acceptance of our methods by the scientific
community; inability to retain or attract key employees whose knowledge is
essential to the development of our products; unforeseen scientific
difficulties that may develop with our process; greater cost of final product
than anticipated; loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally good results
in real settings; our patents may not be sufficient; and final that products
may harm recipients, all of which could cause the actual results or
performance of Oramed to differ materially from those contemplated in such
forward-looking statements. Except as otherwise required by law, Oramed
undertakes no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. For a more
detailed description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with the
Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Cell: +972-54-792-4438
Office:+972-2-566-0001
Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.